These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 9935053)
21. Detection of neuroendocrine tumors: 99mTc-P829 scintigraphy compared with 111In-pentetreotide scintigraphy. Lebtahi R; Le Cloirec J; Houzard C; Daou D; Sobhani I; Sassolas G; Mignon M; Bourguet P; Le Guludec D J Nucl Med; 2002 Jul; 43(7):889-95. PubMed ID: 12097458 [TBL] [Abstract][Full Text] [Related]
22. Radiolabeled somatostatin analog scintigraphy in differentiated thyroid carcinoma. Tenenbaum F; Lumbroso J; Schlumberger M; Caillou B; Fragu P; Parmentier C J Nucl Med; 1995 May; 36(5):807-10. PubMed ID: 7738653 [TBL] [Abstract][Full Text] [Related]
23. [Indium-111-DTPA-phenyl-pentetreotide somatostatin receptors' scintigraphy in the evaluation of patients with suspected gastro-entero-pancreatic tumors. Comparison with computerized tomography]. Gerasimou GP; Aggelopoulou T; Papanastasiou E; Konidari-Dedousi E; Prousalidis I; Psarrakos K; Siountas A; Molybda E; Gotzamani-Psarrakou A Hell J Nucl Med; 2007; 10(3):209-14. PubMed ID: 18084669 [TBL] [Abstract][Full Text] [Related]
24. Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings. Adams S; Baum RP; Hertel A; Schumm-Draeger PM; Usadel KH; Hör G Eur J Nucl Med; 1998 Sep; 25(9):1277-83. PubMed ID: 9724377 [TBL] [Abstract][Full Text] [Related]
25. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. Lebtahi R; Cadiot G; Sarda L; Daou D; Faraggi M; Petegnief Y; Mignon M; le Guludec D J Nucl Med; 1997 Jun; 38(6):853-8. PubMed ID: 9189129 [TBL] [Abstract][Full Text] [Related]
26. [Radionuclide imaging of neurendocrine tumors: biological basis and diagnostic results]. Genovese EA; Mallardo V; Rossi M; Vaccaro A; Raucci A; Della Vecchi N; Romano G; Califano T; Schillirò F Recenti Prog Med; 2013; 104(7-8):340-4. PubMed ID: 24042404 [TBL] [Abstract][Full Text] [Related]
27. [Significance of false-positive findings of somatostatin receptor scintigraphy in diagnosis of neuroendocrine tumors of the gastroenteropancreatic system]. Faiss S; Scherübl H; Bäder M; Fett U; Koppenhagen K; Wiedenmann B; Riecken EO Z Gastroenterol; 1994 May; 32(5):243-6. PubMed ID: 7915450 [TBL] [Abstract][Full Text] [Related]
29. Whole body and tomographic scan with 111In-pentetreotide: preliminary data. Gregianin M; Macrì C; Bui F; Varotto L; Zucchetta P Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):124-6. PubMed ID: 9002769 [TBL] [Abstract][Full Text] [Related]
30. 111In-pentetreotide scintigraphy in the post-thyroidectomy follow-up of patients with medullary thyroid carcinoma. Celentano L; Sullo P; Klain M; Lupoli G; Cascone E; Salvatore M Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):131-3. PubMed ID: 9002771 [TBL] [Abstract][Full Text] [Related]
31. 111In-Pentetreotide uptake in a follicular adenoma of the thyroid gland: a pitfall for 111In-Pentetreotide scintigraphy. Yüksel M; Eziddin S; Wardelmann E; Biersack HJ Rev Esp Med Nucl; 2006 Sep; 25(5):316-9. PubMed ID: 17173778 [TBL] [Abstract][Full Text] [Related]
32. Somatostatin receptor scintigraphy with 111In-pentetreotide in non-functioning gastroenteropancreatic neuroendocrine tumors. Schillaci O; Spanu A; Scopinaro F; Falchi A; Corleto V; Danieli R; Marongiu P; Pisu N; Madeddu G; Delle Fave G; Madeddu G Int J Oncol; 2003 Dec; 23(6):1687-95. PubMed ID: 14612942 [TBL] [Abstract][Full Text] [Related]
37. [Somatostatin receptor status in non-medullary thyroid carcinoma]. Görges R; Kahaly G; Müller-Brand J; Mäcke H; Walgenbach S; Bruns C; Andreas J; Brandt-Mainz K; Bockisch A Nuklearmedizin; 1999; 38(1):15-23. PubMed ID: 9987777 [TBL] [Abstract][Full Text] [Related]
38. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. Kwekkeboom DJ; Kooij PP; Bakker WH; Mäcke HR; Krenning EP J Nucl Med; 1999 May; 40(5):762-7. PubMed ID: 10319747 [TBL] [Abstract][Full Text] [Related]
39. Use of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients without detectable iodine uptake. Garin E; Devillers A; Le Cloirec J; Bernard AM; Lescouarc'h J; Herry JY; Reubi JC; Bourguet P Eur J Nucl Med; 1998 Jul; 25(7):687-94. PubMed ID: 9662589 [TBL] [Abstract][Full Text] [Related]